Clinical Protocol for Hypothermic Oxygenated Perfusion (HOPE) and Controlled Oxygenated Rewarming (COR) of Liver and Kidneys

This clinical protocol outlines the application of Hypothermic Oxygenated Perfusion (HOPE) and Controlled Oxygenated Revascularization (COR) to enhance the quality of donor liver and kidney grafts. The protocol is based on international and domestic studies demonstrating reduced biliary complications and early graft dysfunction rates with machine perfusion. HOPE is recommended for organs from donors after circulatory death (DCD) and extended criteria donors (ECD), while COR is used for assessing marginal organs. The protocol includes detailed descriptions of indications, contraindications, technical aspects of perfusion, monitoring, and viability assessment using biomarkers such as flavin mononucleotide, succinate, and markers of apoptosis, necroptosis, and ferroptosis. The authors present their own results, confirming the effectiveness of these methods in reducing complications and improving transplantation outcomes.

1. 1 Schlegel A, Muller X, Kalisvaart M, et al. Outcomes of DCD liver transplantation using organs treated by hypothermic oxygenated perfusion before implantation. Journal of Hepatology. 2019;70:50-57.

2. 2 van Rijn R, Karimian N, Matton APM, et al. Dual hypothermic oxygenated machine perfusion in liver transplants donated after circulatory death. British Journal of Surgery. 2017;104:907-917.

3. 3 Patrono D, Surra A, Catalano G, et al. Hypothermic oxygenated machine perfusion of liver grafts from brain-dead donors. Scientific Reports. 2019;9:9337.

4. 4 Czigany Z, Lurje I, Tolba RH, et al. Machine perfusion for liver transplantation in the era of marginal organs – New kids on the block. Liver International. 2019;39:228-249.

5. 5 Nasralla D, Coussios CC, Mergental H, et al. A randomized trial of normothermic preservation in liver transplantation. Nature. 2018;557:50-56.

6. 6 Schlegel A, Mergental H, Fondevila C, et al. Machine perfusion of the liver and bioengineering. Journal of Hepatology. 2023;78:1181-1198.

7. 7 Moers C, Smits JM, Maathuis MH, et al. Machine perfusion or cold storage in deceased-donor kidney transplantation. New England Journal of Medicine. 2009;360:7-19.

8. 8 Jochmans I, Brat A, Davies L, et al. Oxygenated versus standard cold perfusion preservation in kidney transplantation (COMPARE): a randomised, double-blind, paired, phase 3 trial. Lancet. 2020;396:1653-1662.

9. 9 Hosgood SA, Nicholson ML. First in man renal transplantation after ex vivo normothermic perfusion. Transplantation. 2011;92:735-738.

10. 10 Kaths JM, Echeverri J, Linares I, et al. Normothermic ex vivo kidney perfusion for graft quality assessment prior to transplantation. American Journal of Transplantation. 2018;18:580-589.

11. 11 van Leeuwen OB, de Vries Y, Fujiyoshi M, et al. Transplantation of high-risk donor livers after ex situ resuscitation and assessment using combined hypo- and normothermic machine perfusion: a prospective clinical trial. Annals of Surgery. 2019;270:906-914.

12. 12 Mergental H, Laing RW, Kirkham AJ, et al. Transplantation of discarded livers following viability testing with normothermic machine perfusion. Nature Communications. 2020;11:2939.

13. 13 Hoyer DP, Mathe Z, Gallinat A, et al. Controlled oxygenated rewarming of cold stored livers prior to transplantation: First clinical application of a new concept. Transplantation. 2016;100:147-152.

14. 14 Schlegel A, Kron P, Graf R, et al. Warm vs. cold perfusion techniques to rescue rodent liver grafts. Journal of Hepatology. 2014;61:1267-1275.

15. 15 Dutkowski P, Polak WG, Muiesan P, et al. First comparison of hypothermic oxygenated perfusion versus static cold storage of human donation after cardiac death liver transplants: an international-matched case analysis. Annals of Surgery. 2015;262:764-770.

16. 16 Bruinsma BG, Yeh H, Özer S, et al. Subnormothermic machine perfusion for ex vivo preservation and recovery of the human liver for transplantation. American Journal of Transplantation. 2014;14:1400-1409.

17. 17 Ravaioli M, De Pace V, Angeletti A, et al. Hypothermic oxygenated new machine perfusion system in liver and kidney transplantation of extended criteria donors: first Italian clinical trial. Scientific Reports. 2020;10:6063.

18. 18 Detelich D, Markmann JF. The dawn of liver perfusion machines. Current Opinion in Organ Transplantation. 2018;23:151-161.

19. 19 Karangwa SA, Dutkowski P, Fontes P, et al. Machine perfusion of donor livers for transplantation: a proposal for standardized nomenclature and reporting guidelines. American Journal of Transplantation. 2016;16:2932-2942.

20. 20 van Leeuwen OB, de Vries Y, Fujiyoshi M, et al. Flavin mononucleotide during ex vivo machine perfusion is a reliable predictor of human donor liver viability and post-transplant graft recovery. Liver Transplantation. 2022;28:1699-1709.

21. 21 de Vries Y, Matton APM, Nijsten MWN, et al. Pretransplant sequential hypo- and normothermic machine perfusion of suboptimal livers donated after circulatory death using a hemoglobin-based oxygen carrier perfusion solution. American Journal of Transplantation. 2019;19:1202-1211.

22. 22 Stockwell BR, Friedmann Angeli JP, Bayir H, et al. Ferroptosis: A Regulated Cell Death Nexus Linking Metabolism, Redox Biology, and Disease. Cell. 2017;171:273-285.

23. 23 Dixon SJ, Lemberg KM, Lamprecht MR, et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell. 2012;149:1060-1072.

24. 24 Yang WS, SriRamaratnam R, Welsch ME, et al. Regulation of ferroptotic cancer cell death by GPX4. Cell. 2014;156:317-331.

25. 25 Doll S, Freitas FP, Shah R, et al. FSP1 is a glutathione-independent ferroptosis suppressor. Nature. 2019;575:693-698.

26. 26 Bersuker K, Hendricks JM, Li Z, et al. The CoQ oxidoreductase FSP1 acts parallel to GPX4 to inhibit ferroptosis. Nature. 2019;575:688-692.

27. 27 Friedmann Angeli JP, Schneider M, Proneth B, et al. Inactivation of the ferroptosis regulator Gpx4 triggers acute renal failure in mice. Nature Cell Biology. 2014;16:1180-1191.

28. 28 Linkermann A, Skouta R, Himmerkus N, et al. Synchronized renal tubular cell death involves ferroptosis. Proceedings of the National Academy of Sciences. 2014;111:16836-16841.

29. 29 Li Y, Feng D, Wang Z, et al. Ischemia-induced ACSL4 activation contributes to ferroptosis-mediated tissue injury in intestinal ischemia/reperfusion. Cell Death and Differentiation. 2019;26:2284-2299.

30. 30 Yamada N, Karasawa T, Wakiya T, et al. Ferroptosis driven by radical oxidation of n-6 polyunsaturated fatty acids mediates hepatotoxicity and tumorigenesis. Cell Metabolism. 2020;32:144-159.

31. 31 Kagan VE, Mao G, Qu F, et al. Oxidized arachidonic and adrenic PEs navigate cells to ferroptosis. Nature Chemical Biology. 2017;13:81-90.

32. 32 Wenzel SE, Tyurina YY, Zhao J, et al. PEBP1 wardens ferroptosis by enabling lipoxygenase generation of lipid death signals. Cell. 2017;171:628-641.

33. 33 Doll S, Proneth B, Tyurina YY, et al. ACSL4 dictates ferroptosis sensitivity by shaping cellular lipid composition. Nature Chemical Biology. 2017;13:91-98.

34. 34 Mayr L, Grabherr F, Schwärzler J, et al. Dietary lipids fuel GPX4-restricted enteritis resembling Crohn's disease. Nature Communications. 2020;11:1775.

35. 35 Degterev A, Huang Z, Boyce M, et al. Chemical inhibitor of nonapoptotic cell death with therapeutic potential for ischemic brain injury. Nature Chemical Biology. 2005;1:112-119.

36. 36 Linkermann A, Bräsen JH, Darding M, et al. Two independent pathways of regulated necrosis mediate ischemia-reperfusion injury. Proceedings of the National Academy of Sciences. 2013;110:12024-12029.

37. 37 Muller T, Dewitz C, Schmitz J, et al. Necroptosis and ferroptosis are alternative cell death pathways that operate in acute kidney failure. Cellular and Molecular Life Sciences. 2017;74:3631-3645.

38. 38 Zhang Y, Su SS, Zhao S, et al. RIP1 autophosphorylation is promoted by mitochondrial ROS and is essential for RIP3 recruitment into necrosome. Nature Communications. 2017;8:14329.

39. 39 Sun L, Wang H, Wang Z, et al. Mixed lineage kinase domain-like protein mediates necrosis signaling downstream of RIP3 kinase. Cell. 2012;148:213-227.

40. 40 Choi ME, Price DR, Ryter SW, Choi AMK. Necroptosis: a crucial pathogenic mediator of human disease. JCI Insight. 2019;4:e128834.